Jeffrey P. Mornhinweg

Array ( [id] => 16012721 [patent_doc_number] => 20200181203 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => COVALENTLY FUSED VIRAL COAT PROTEINS FOR THE DISPLAY OF TARGET MOLECULES [patent_app_type] => utility [patent_app_number] => 16/346315 [patent_app_country] => US [patent_app_date] => 2017-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9354 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16346315 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16648804 [patent_doc_number] => 10925958 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-23 [patent_title] => Influenza vaccine [patent_app_type] => utility [patent_app_number] => 16/348943 [patent_app_country] => US [patent_app_date] => 2017-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 35553 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 76 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348943 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15678505 [patent_doc_number] => 20200093916 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-26 [patent_title] => NOVEL RECOMBINANT HIV COMPOSITIONS AND USES THEREOF IN ANIMAL MODELS [patent_app_type] => utility [patent_app_number] => 16/348104 [patent_app_country] => US [patent_app_date] => 2017-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5811 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348104 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14926365 [patent_doc_number] => 20190298820 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-10-03 [patent_title] => NOVEL RECOMBINANT HIV EPITOPES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/348097 [patent_app_country] => US [patent_app_date] => 2017-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6985 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16348097 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15785367 [patent_doc_number] => 10626394 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-04-21 [patent_title] => Synthetic bacteriophages and bacteriophage compositions [patent_app_type] => utility [patent_app_number] => 15/795510 [patent_app_country] => US [patent_app_date] => 2017-10-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 65 [patent_no_of_words] => 25854 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 68 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15795510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15524861 [patent_doc_number] => 20200054736 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => USE OF ENDOGENOUS VIRAL VACCINE IN CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY [patent_app_type] => utility [patent_app_number] => 16/342426 [patent_app_country] => US [patent_app_date] => 2017-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 58774 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -56 [patent_words_short_claim] => 79 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16342426 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17162995 [patent_doc_number] => 11149082 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-19 [patent_title] => Multispecific antibodies targeting human immunodeficiency virus and methods of using the same [patent_app_type] => utility [patent_app_number] => 16/342962 [patent_app_country] => US [patent_app_date] => 2017-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 68 [patent_figures_cnt] => 48 [patent_no_of_words] => 44644 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 187 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16342962 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15527191 [patent_doc_number] => 20200055901 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => SIGNATURE-BASED HUMAN IMMUNODEFICIENCY VIRUS (HIV) ENVELOPE (ENV) TRIMER VACCINES AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/342866 [patent_app_country] => US [patent_app_date] => 2017-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42230 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -229 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16342866 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15086367 [patent_doc_number] => 20190337994 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-07 [patent_title] => PRODUCTION OF SOLUBLE HIV ENVELOPE TRIMERS IN PLANTA [patent_app_type] => utility [patent_app_number] => 16/382933 [patent_app_country] => US [patent_app_date] => 2017-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8550 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 166 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16382933 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14649477 [patent_doc_number] => 20190231867 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/336732 [patent_app_country] => US [patent_app_date] => 2017-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49808 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -128 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16336732 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15435449 [patent_doc_number] => 20200031908 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => METHODS TO IDENTIFY IMMUNOGENS BY TARGETING IMPROBABLE MUTATIONS [patent_app_type] => utility [patent_app_number] => 16/337264 [patent_app_country] => US [patent_app_date] => 2017-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31511 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16337264 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14132733 [patent_doc_number] => 20190100756 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => CpG-OLIGODEOXYNUCLEOTIDE, IMMUNOGENIC COMPOSITION INCLUDING THE SAME, AND METHOD OF INDUCING IMMUNE RESPONSE BY THE SAME [patent_app_type] => utility [patent_app_number] => 15/722949 [patent_app_country] => US [patent_app_date] => 2017-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5298 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15722949 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15435959 [patent_doc_number] => 20200032163 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => Method for the Virus Inactivation of a Preparation of Monoclonal Antibodies [patent_app_type] => utility [patent_app_number] => 16/337004 [patent_app_country] => US [patent_app_date] => 2017-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9214 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16337004 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15553525 [patent_doc_number] => 20200061174 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => Compositions and Methods for Enhancing the Stability of Transgenes in Poxviruses [patent_app_type] => utility [patent_app_number] => 16/337086 [patent_app_country] => US [patent_app_date] => 2017-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17811 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16337086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14652695 [patent_doc_number] => 20190233476 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES [patent_app_type] => utility [patent_app_number] => 16/335099 [patent_app_country] => US [patent_app_date] => 2017-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28837 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -57 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13763491 [patent_doc_number] => 10174080 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-08 [patent_title] => Compositions for preventing and/or treating an infection by an HIV-1 virus [patent_app_type] => utility [patent_app_number] => 15/712195 [patent_app_country] => US [patent_app_date] => 2017-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 19 [patent_no_of_words] => 18755 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 184 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15712195 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16012799 [patent_doc_number] => 20200181242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => Compositions and Methods for Identifying and Sorting Antigen-Specific B Cells [patent_app_type] => utility [patent_app_number] => 16/335891 [patent_app_country] => US [patent_app_date] => 2017-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10804 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16335891 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14581337 [patent_doc_number] => 20190218277 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-18 [patent_title] => ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/333736 [patent_app_country] => US [patent_app_date] => 2017-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42313 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16333736 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14531809 [patent_doc_number] => 20190201525 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => COMBINING ADENOVIRUS AND CHECKPOINT INHIBITORS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 16/330274 [patent_app_country] => US [patent_app_date] => 2017-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12697 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16330274 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13077103 [patent_doc_number] => 10058606 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-08-28 [patent_title] => Hepatitis B therapeutic vaccines [patent_app_type] => utility [patent_app_number] => 15/701352 [patent_app_country] => US [patent_app_date] => 2017-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 13 [patent_no_of_words] => 7071 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 194 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15701352 [rel_patent_id] =>[rel_patent_doc_number] =>)